Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home OCT-Guided Treatment vs Treat and Extend in nAMD
NCT05904028Phase 3Active, not recruiting
- Sponsor
- Jaeb Center for Health Research
- Start
- Nov 2023
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of faricimab in neovascular age-related macular degeneration (NVAMD), sponsored by Jaeb Center for Health Research. Started Nov 2023; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05904028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904028.